JC02 Rec'd PCT/PTO 12 MAY 2005

, pot-

Under the Paperwork Red

Alexandria, VA 22313-1450 on the date shown below.

Paul K. Legaard

Signature

Typed or printed name

Approved U.S. Patent and Trademark ct of 1995, no persons are required to respond to a collection of information

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark
U.S. DEPARTMENT OF COMMERCE
pond to a collection of information in displays a valid OMB control number.

		P ^{1,5} e, b			
TOWNCASITTAL	Application Number	er	10/528,640		
TRANSMITTAL	Filing Date		Dc7082e 2, 2003		
4		First Named Inven	itor	Becker	
MAY 1 2 2005	Art Unit		Not Yet Assigned		
to be used for all conespondence after	initial filina)	Examiner Name		Not Yet Assigned	
Total Numbe Abit ages in This Submiss		Attorney Docket N	umber	ASZN0019-100 (100848-1P US)	
	ENCLO	SURES (check all tha	at apply)		
Fee Transmittal Form	☐ Drawing(s			After Allowance Communication to TC	
Fee Attached	Licensing	-related Papers		Appeal Communication to Board of Appeals and Interferences	
Amendment / Reply	Petition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
After Final		Convert to a al Application		☐ Proprietary Information	
Affidavits/declaration(s)		Attorney, Revocation of Correspondence Add	tress	Status Letter	
Extension of Time Request	Terminal (Disclaimer		Other Enclosure(s) (please identify below):	
Express Abandonment Request	Request f	or Refund		- Table A - Statement Under 37 CFR 3.73(b)	
☐ Information Disclosure Statement		idscape Table on CD		- executed Assignment - Return Postcard	
Certified Copy of Priority Document(s)	Remarks	·			
Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR1.52 or 1.53	Application o Missing Parts 7 CFR1.52 or 1.53				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Cozen O'Connor, P.C.					
Signature	Palle				
Printed Name	Paul K. Legaard	i			
Date	lono	4 2005	Reg. No.	38,534	
	CERTIFICA	TE OF TRANSMISS	SION/MAI	LING	
				or deposited with the United States Postal Commissioner for Patents, P.O. Box 1450,	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

10 may

205

TABLE A

Our Ref.	Serial No.	First Inventor	Examiner	Title
AstraZeneca Ref.	Filing Date		Art Unit	
ASZN0005-100 100368-1P US	10/477,851 5/16/02	Brown	Rita J. Desai 1625	4-(phenyl-piperidin-4-ylidene-methyl)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders
ASZN0005-101 100369-1P US	10/477,854 5/16/02	Brown	Celia C. Chang 1625	4-(phenyl-piperdin-4-ylidene-methyl)-benzamide Derivative And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders
ASZN0005-102 100372-1P US	10/477,853 5/16/02	Brown	Rita J. Desai 1625	4-(Phenyl-(piperidin-4-yl)-amino)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders
ASZN0005-103 100373-1P US	10/477,633 5/16/02	Brown	Rita J. Desai 1625	4-(phenyl-(piperidin-4yl)-amino)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders
ASZN0005-104 100375-1P US	10/477,636 5/16/02	Brown	Rita J. Desai 1625	4-(phenyl-(piperidin-4yl)-amino)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders
ASZN0006-100 100514-1P US	10/497,565 12/11/02	Leung	Not Yet Assigned	Benzodiazepine Derivatives, Preparation Thereof And Use Thereof
ASZN0007-100 100590-1P US	10/498,864 12/17/02	Cheng	Not Yet Assigned	Therapeutic Heterocycles
ASZN0008-100 100100-1P US	10/333,669 1/21/03	Patel	Raymond K. Covington 1625	Process For Asymmetric Synthesis Of Substituted 1,4- Dihydropyridines
ASZN0009-100 100102-1P US	10/333,654 9/5/03	Patel	Alton N. Pryor 1616	Process For Synthesis Of Alpha, Beta-unsaturated Ketones

. ,			r ·	r	 	Rec'	d PCT	/PTO	12 M	AY 2005
Method For The Treatment Of Overactive Bladder Compounds And Method For The Treatment Of Overactive Bladder	Method	N-type Calcium Channel Antagonists For The Treatment Of Pain	N-type Calcium Channel Antagonists For The Treatment Of Pain	N-type Calcium Channel Antagonists For The Treatment Of Pain	Cd45 Inhibitors	Cd45 Inhibitors	N-(2-phenyl-3-aminopropyl)naphtamides	Cyclized Benzamide Neurokinin Antagonists For Use Therapy	Compounds	
Raymond J. Henley III 1614 Not Yet Assigned	D. Margaret M. Seaman 1625	Not Yet Assigned 1614	D. Margaret M. Seaman 1625	Not Yet Assigned	Maury A. Audet 1654	Kevin Weddington 1614	Shailendra Kumar 1621	Bruck Kifle 1624	Celia C. Chang 1625	2
Bialecki Bialecki	Jones	Chapdelaine	D'Amico	D'Amico	Chapdelaine	Chapdelaine	Bernstein	Bernstein	Shenvi	
10/494,387 4/30/04 10/494,195 11/1/02	10/502,191	10/415,853	10/488,066 8/9/04	10/488,025 8/23/02	10/168,758 11/25/02	10/168,477 11/25/02	10/333,658 7/31/01	10/381,755 3/26/03	10/450,284 12/20/01	·
ASZN0010-100 100541-1P US ASZN0010-101 100542-1P US	ASZN0011-100 100570-1P US	ASZN0012-100 100186-1P US	ASZN0012-101 100463-1P US	ASZN0012-102 100464-1P US	ASZN0013-100 Z70624-1P US	ASZN0013-101 Z70626-1P US	ASZN0014-100 100121-1P US	ASZN0015-100 100174-1P US	ASZN0016-100 100237-1P US	

			,	
ASZN0017-100 Z70402-1P US	09/806,657 10/4/99	Bernstein	Not Yet Assigned	Naphthalenecarboxamides As Tachykinin Receptor Antagonists
ASZN0018-100 100003-2P US	11/042,752 1/24/05	Albert	Not Yet Assigned	Neurokinin Antagonists For Use As Medicaments
ASZN0019-100 100848-1P US	10/528,640 10/2/03	Becker	Not Yet Assigned	Novel Lactams And Uses Thereof



TED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT UNDER 37 CFR 3.73(b)

Applicant, AstraZeneca AB, a corporation, states that it is:

the assignee of the entire right, title, and interest of the applications identified in Table A attached hereto.

The extent (by, percentage) of its ownership interest is 100% in the patent applications identified in Table A by virtue of:

a copy of the pertinent assignment from the inventor(s) of the patent applications identified in Table A is enclosed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,

ASTRAZENECA AB

Date: __13 April 20054

Name: Christer Wahlström

Title: Director Patent Operations



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Date: 13 April 2005

Sir:

POWER OF ATTORNEY WITH REVOCATION AND CHANGE OF CORRESPONDENCE ADDRESS

I hereby revoke all previous powers of attorney or authorizations of agent given in the applications identified in Table A attached hereto, and appoint

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the Correspondence Address for all applications identified in Table A to:

| Practitioners at Customer Number 52286

I am the:

| Applicant/Inventor.
| Assignee of record of the entire interest. (A statement under 37 CFR 3.73(b) is enclosed.)

| Respectfully submitted, ASTRAZENECA AB

Title: Director Patent Operations

Name: Christer Wahlström

ATTORNEY DOCKET NO.: AstraZeneca Ref.: 100848-1P US

ASSIGNMENT

Now, therefore, for good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, I/we

Christopher BECKER, Bruce DEMBOFSKY, Robert JACOBS, James KANG, Cyrus OHNMACHT, James ROSAMOND, Ashokkumar Bhikkappa SHENVI, Thomas SIMPSON and James WOODS all of AstraZeneca Wilmington, P.O. Box 15437, Wilmington, DE 19850-5437, USA

hereafter referred to as ASSIGNOR (S),

Hereby sell(s), assign(s) and transfer(s) to ASSIGNEE AstraZeneca AB, a company created and existing under the laws of Sweden, having its Head Office at SE-151 85 Södertalje, Sweden, and the successors, assigns and legal representatives of the ASSIGNEE, the entire right, title and interest for the United States and its territorial possessions, and in all foreign countries, in and to the inventions and any and all improvements thereon which are the subject of an application entitled:

NOVEL LACTAMS AND USES THEREOF

Aliu Wilich is disclosed III.	And	which	is	disclosed	in:	
-------------------------------	-----	-------	----	-----------	-----	--

(a) 🗌	U.S. patent application executed on even date herewith;
(b) 🗌	U.S. patent application executed on;
(c) 🗌	U.S. application no;
(d) 🔯	International application no. PCT/SE2003/001534 filed on 2 October 2003

And in and to the above application and any legal equivalent thereof in a foreign country, including the right to claim priority, and in and to any division, continuation or continuation-in-part, renewal or substitute thereof, and in and to all resulting Letters Patents or any reissue or reexamination thereof, to have and to hold the same to the full end of the term or terms for which any and all of said Letters Patent may be granted;

ASSGNOR(S) authorize(s) and request(s) the issuing authority to issue any and all patents on said application or applications to said ASSIGNEE or its successors and assigns;

ASSIGNOR(S) hereby covenant(s) that ASSIGNOR(S) has/have the full power to make this assignment, and that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment; and

Without further payment or compensation by the ASSIGNEE or its successors and assigns, ASSIGNOR(S) further covenant(s) and agree(s) to communicate to said ASSIGNEE or its representatives, agents, its successors or assigns, any facts relating to said invention or inventions including evidence for purposes of interference or other administrative or legal proceedings whenever requested; to testify in any interference, legal or administrative proceedings, whenever requested; to execute and deliver, on request, all lawful papers required to make any of the foregoing provisions effective; and to do everything possible to aid said ASSIGNEE, its successors or assigns and nominees to secure, obtain and enforce proper patent protection for said invention or inventions in this or any foreign country.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

IN WITNESS WHEREOF, I have hereunto set my hand and seal on the date below written.

Ohn John Becker Christopher BECKER	3/14/05
Signature of Assignor	Date of Assignor's Signature
WITNESSED BY:	
Elizabeth Whitenss Signature of Witness Name of WitnessElizabeth Ashlen (Type or print clearly)	Signature of Witness Name of Witness (Type or print clearly)
IN WITNESS WHEREOF, I have hereunto set my han	nd and seal on the date below written.
Bruce DEMBOFSKY Signature of Assignor	2/2//2005 Date of Assignor's Signature
WITNESSED BY: Eugabeth ashton Signature of Witness Name of Witness Elizabeth Ashton	Signature of Witness
(Type or print clearly)	Name of Witness FRANCES TOUTKALDJIAN (Type or print clearly)
IN WITNESS WHEREOF, I have hereunto set my han	d and seal on the date below written.
Robert JACOBS	3/7/2005
Signature of Assignor	Date of Assignor's Signature
WITNESSED BY:	
Cluarth Ashtan Signature of Witness	Signature of Witness
Name of Witness Elizabeth Ashton (Type or print clearly)	Name of Witness FRANCES TOW KALDIAN
Additional signature pages attached: ✓ Yes ✓ No	

IN WITNESS WHEREOF, I have hereunto set my hand	d and seal on the date below written.
James KANG Signature of Assignor	3-7-05 Date of Assignor's Signature
WITNESSED BY:	The Arch
Signature of Witness Name of Witness Elizabeth Ashtm (Type or print clearly)	Signature of Witness Name of Witness Frean Towks Aud Jian (Type or print clearly)
IN WITNESS WHEREOF, I have hereunto set my hand	d and seal on the date below written.
Cyrus Ohnmacht Signature of Assignor	2/28/05 Date of Assignor's Signature
WITNESSED BY: Lizabeth Aphton	Fron Pombaco
Signature of Witness Name of Witness Elizabeth Ashten (Type or print clearly)	Signature of Witness Name of Witness FRAN TOUTKALDJUAN (Type or print clearly)
IN WITNESS WHEREOF, I have hereunto set my hand	and seal on the date below written.
James ROSAMOND Signature of Assignor	Z/27/85 Date of Assignor's Signature
WITNESSED BY:	
Signature of Witness Name of Witness Elizabeth Ashton (Type or print clearly)	Signature of Witness Name of Witness (Type or print clearly) FRAN TOWKAWJIAN
Additional signature pages attached: Yes No	

IN WITNESS WHEREOF, I have hereunto set my hand and seal on the date below written.

Ashokkumar Bhikkappa SHENVI Signature of Assignor	Date of Assignor's Signature
WITNESSED BY: Life Little Content Signature of Witness Name of Witness Elizabeth Ashton (Type or print clearly)	Signature of Witness Name of Witness (Type or print clearly)
IN WITNESS WHEREOF, I have hereunto set my hare the management of Assignor	nd and seal on the date below written. 2 2 5 05 Date of Assignor's Signature
WITNESSED BY: Linalith Anton Signature of Witness Name of Witness Elizabeth Ashton (Type or print clearly)	Signature of Witness Name of Witness (Type or print clearly)
IN WITNESS WHEREOF, I have hereunto set my har	and and seal on the date below written. $2/25/05$
Signature of Assignor WITNESSED BY: Cligateth Continues Signature of Witness Name of Witness Name of Witness Type or print clearly)	Signature of Witness Name of Witness (Type or print clearly)
Additional signature pages attached: \(\text{Yes} \) \(\text{X} \)	